Video

Can Biosimilars Reduce Specialty Spending?

Author(s):

Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Related Videos
Image credit: JJAVA | stock.adobe.com
Related Content
Gene editing in chronic hepatitis B -- Image credit: 红 王 | stock.adobe.com
April 22nd 2025

PBGENE-HBV Granted FDA Fast Track Designation for Chronic Hepatitis B

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
A Pharmacist’s Guide to Blockbuster Patent Expirations: 2025 and Beyond
April 18th 2025

A Pharmacist’s Guide to Blockbuster Patent Expirations: 2025 and Beyond

Sanam Kolia, PharmD, RPh
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Pharmacist Spotlight: Adenike Atanda-Oshikoya, PharmD, BCACP, CDCES, CTTS
April 17th 2025

Pharmacist Spotlight: Adenike Atanda-Oshikoya, PharmD, BCACP, CDCES, CTTS

PT Staff Adenike Atanda-Oshikoya, PharmD, BCACP, CDCES, CTTS
Gut health -- Image credit: sdecoret | stock.adobe.com
April 16th 2025

Essential Immune Cells in Intestine Cause Gut Inflammation, Allergic Responses to Foods When Absent

Gillian McGovern, Associate Editor